Moderna says FDA refuses to review its application for experimental flu shot [CNBC]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: CNBC
It's another sign of the Trump administration's influence on tightening vaccine regulation in the U.S. Moderna said the move is inconsistent with previous feedback the FDA gave before it submitted the application and started phase three trials on the shot, called mRNA-1010, and that the agency did not identify any specific safety or efficacy issues with the vaccine. In this article A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration refused to start a review of Moderna 's application for its experimental flu shot, the company announced Tuesday, in another sign of the Trump administration's influence on tightening vaccine regulations in the U.S. Moderna said the move is inconsistent with previous feedback from the agency from before it submitted the application and started phase three trials on the shot, called mRNA-1010. The dru
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.GlobeNewswire
- Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Moderna (NASDAQ:MRNA) had its "hold" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $25.00 price target on the stock.MarketBeat
MRNA
Earnings
- 2/13/26 - Beat
MRNA
Sec Filings
- 2/13/26 - Form 8-K
- 2/11/26 - Form 8-K
- 2/9/26 - Form SCHEDULE
- MRNA's page on the SEC website